In addition to the mechanism behind the rare form of thrombosis, according to researchers, they have also developed a diagnostic tool and a suggested therapy to “clarify it immediately,” the German international channel reported on Friday.
The revelation came as European countries resumed dosing, developed by the British-Swedish pharmaceutical company and the British University of Oxford, after days of suspension for fears about blood clots that caused death in some cases.
Deutsche Welle reported the findings of researchers at the Greifswald teaching hospital in northern Germany citing public broadcaster Norddeutscher Rundfunk.
Research showed how the vaccine caused rare thrombosis in the brain in a small number of patients, according to the report.
“The discovery means that targeted treatment can be offered to those who suffer from similar clotting with a very common drug,” he said.
The success was the result of cooperation between Greifswald Hospital, the state health regulator at the Paul Ehrlich Institute, and doctors in Austria.
The researchers stressed that treatment would only be possible in patients where blood clots appear, rather than as a preventative treatment.
Symptoms such as continuous headache, dizziness or impaired vision that last more than three days after vaccination need further medical check-ups, according to the report, which cites a statement from the German Research Association on Thrombosis and Hemostasis .
Greifswald’s findings have not yet been published in a scientific journal and have therefore not been reviewed by independent experts. The Paul-Ehrlich Institute in Germany is now studying the work of scientists.